<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04276298</url>
  </required_header>
  <id_info>
    <org_study_id>APH MDL</org_study_id>
    <nct_id>NCT04276298</nct_id>
  </id_info>
  <brief_title>Combination Topical Analgesia Post Haemorrhoidectomy: a Study on Metronidazole, Diltiazem and Lignocaine</brief_title>
  <official_title>A Multi-arm Randomized Clinical Trial on Combination Topical Analgesia Post-haemorrhoidectomy: a Study on Metronidazole, Diltiazem and Lignocaine.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Auckland, New Zealand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Auckland, New Zealand</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-arm RCT on the effect of combination metronidazole, diltiazem and lignocaine applied
      topically on post haemorrhoidectomy pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multi arm RCT will be randomized 1:1:1:1 Mutli-centre recruitment will take place across
      the Auckland Region. We will recruit 52 patients across each arm. Treatment will be either
      metronidazole alone, or combination metronidazole and diltiazem or combination metronidazole
      and lignocaine or combination metronidazole, diltiazem and lignocaine. primary outcome will
      be visual acuity pain score and amount of analgesics used.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Double blinded trial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pain scores</measure>
    <time_frame>day 4</time_frame>
    <description>Measured by Visual acuity score, 1-10 the higher the score, the worse the pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of analgesic use</measure>
    <time_frame>day 4</time_frame>
    <description>Morphine equivalent amount</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Before and after Microbiome analysis</measure>
    <time_frame>day 4</time_frame>
    <description>rectal swab taken to analyse the microbiome of wound size</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Validation of Haemorrhoid Severity Score</measure>
    <time_frame>Before surgery and 6 weeks post surgery</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">212</enrollment>
  <condition>Hemorrhoid Pain</condition>
  <condition>Hemorrhoids</condition>
  <arm_group>
    <arm_group_label>Metronidazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A receiving 10% metronidazole cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metronidazole + Diltiazem</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metronidazole 10% + Diltiazem 2%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metronidazole + Lignocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metronidazole 10% + Lignocaine 4%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metronidazole + Diltiazem + Lignocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metronidazole 10% + Diltiazem 2% + Lignocaine 4%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole cream</intervention_name>
    <description>10% metronidazole applied rectally</description>
    <arm_group_label>Metronidazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Combination Metronidazole and Diltiazem</intervention_name>
    <description>Combination Metronidazole and Diltiazem applied rectally</description>
    <arm_group_label>Metronidazole + Diltiazem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Combination Metronidazole and Lignocaine</intervention_name>
    <description>Combination metronidazole and lignocaine applied rectally</description>
    <arm_group_label>Metronidazole + Lignocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination Metronidazole, Diltiazem and Lignocaine</intervention_name>
    <description>Combination of all active agents tested applied rectally</description>
    <arm_group_label>Metronidazole + Diltiazem + Lignocaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥16

          -  All patients undergoing excisional haemorrhoidectomy

        Exclusion Criteria: • Age &lt;16

          -  Have a simultaneous operation other than excisional haemorrhoidectomy

          -  History of chronic pain

          -  Previous allergy/adverse reaction to metronidazole, diltiazem or lignocaine.

          -  Unable to consent or complete data questionnaires due to cognitive impairment

          -  Pregnancy, or breastfeeding given Class B status of metronidazole medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>James Jin, MBChB</last_name>
    <phone>6421 0235 1160</phone>
    <email>james.jin@auckland.ac.nz</email>
  </overall_contact>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 17, 2020</study_first_submitted>
  <study_first_submitted_qc>February 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2020</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Auckland, New Zealand</investigator_affiliation>
    <investigator_full_name>Andrew G Hill, MBChB, MD (Thesis), EdD, FACS, FRACS</investigator_full_name>
    <investigator_title>Professor of Surgery, Head of School</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhoids</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Diltiazem</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Will be shared when results become available.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>When results are available for 12 months</ipd_time_frame>
    <ipd_access_criteria>email request</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

